Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.65 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.63 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | SRC | P12931 | 2/20 | 0.63 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.63 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.63 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.63 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.63 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.63 |
| ▸ | LDHA | P00338 | 1/20 | 0.63 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.63 |
| ▸ | FBP1 | P09467 | 1/20 | 0.63 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.63 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18522039 | 1.00 | NT5E (0.65) | NT5EP2RY1P2RY2SMN1; SMN2SRC | |
| SCHEMBL22381606 | 1.00 | NT5E (0.65) | NT5EP2RY1P2RY2SMN1; SMN2SRC | |
| SCHEMBL18520792 | 1.00 | NT5E (0.65) | NT5EP2RY1P2RY2SMN1; SMN2SRC | |
| SCHEMBL22326716 | 0.94 | ADORA3 (0.57) | NT5EP2RY1P2RY2SMN1; SMN2SRC | |
| SCHEMBL22399590 | 0.94 | NT5E (0.63) | NT5EP2RY1P2RY2SMN1; SMN2SRC | |
| SCHEMBL22381541 | 0.94 | NT5E (0.63) | NT5EP2RY1P2RY2SMN1; SMN2SRC | |
| SCHEMBL18521693 | 0.94 | NT5E (0.63) | NT5EP2RY1P2RY2SMN1; SMN2SRC | |
| SCHEMBL18521684 | 0.94 | NT5E (0.63) | NT5EP2RY1P2RY2SMN1; SMN2SRC | |
| SCHEMBL24499275 | 0.94 | NT5E (0.56) | NT5EP2RY1P2RY2SMN1; SMN2SRC | |
| SCHEMBL18521324 | 0.94 | NT5E (0.62) | NT5EP2RY1P2RY2SMN1; SMN2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | US | disclosed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2019-10-31 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | NT5E 1372/4885P2RY1 34/4885P2RY2 88/4885 |
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | NT5E 388/4885P2RY1 191/4885P2RY2 368/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | NT5E 1372/4885P2RY1 34/4885P2RY2 88/4885 |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | NT5E 1372/4885P2RY1 34/4885P2RY2 88/4885 |
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | STING1, CGAS, IRF3 | NT5E 56/4885P2RY1 30/4885P2RY2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.